Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has maintained a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and lowered the price target from $190 to $170.
October 16, 2023 | 4:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alnylam Pharmaceuticals' price target has been lowered from $190 to $170 by Cantor Fitzgerald, while maintaining a Neutral rating.
The lowering of the price target by Cantor Fitzgerald indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Alnylam Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100